KRAS-C9, K-Ras(G12C) Inhibitor
Overview | |
Catalog # | bs-60219c-2-mg-solid |
Product Name | KRAS-C9, K-Ras(G12C) Inhibitor |
Specifications | |
Storage Buffer | Powder |
Storage Condition | Store in dry, dark place at -20C for 1 year. |
Target | |
Product Information | Molecular Weight: 513.78 Formula: C16 H21 Cl I N3 O4 S CAS Number: 1469337-91-4 InChi Key: ZGUSBCDCZNBNQT-UHFFFAOYSA-N InChi: InChI=1S/C16H21ClIN3O4S/c1-3-26(23,24)20-11-4-6-21(7-5-11)16(22)10-19-14-9-13(18)12(17)8-15(14)25-2/h3,8-9,11,19-20H,1,4-7,10H2,2H3 Smiles: COC1C=C(Cl)C(I)=CC=1NCC(=O)N1CCC(CC1)NS(=O)(=O)C=C Purity: 98.0 Solubility: DMSO up to 100 mM Appearance: Solid Power. Shelf Life: 1.0 years |
Description | KRAS-C9 is a potent and selective allosteric inhibitor of oncogenic K-Ras(G12C). It irreversibly binds to a common oncogenic mutant K-Ras(G12C) and blocks K-Ras(G12C) interactions, therefore does not affect the wild-type protein. Binding of KRAS-C9 to K-Ras(G12C) disrupts both switch-I and switch-II, subverting the native nucleotide preference to favour GDP over GTP and impairing binding to Raf. It can decrease viability and increase apoptosis of K-Ras(G12C)-containing cancer cell lines. KRAS-C9 provides structure-based validation of a new allosteric regulatory site on Ras that is targetable in a mutant-specific manner. |